Sorrento rises after promising data on lung cancer drug

Sorrento Therapeutics

23/08/2022 17:24

** Shares of Sorrento Therapeutics Inc  SRNE.O  rise 5.4% to
$1.87 
    ** Says a review of long-term data showed its drug
abivertinib demonstrated significant treatment benefits in a key
study among patients with non-small cell lung cancer  urn:newsml:reuters.com:*:nGNXmgnmm
    ** In the study, 56.5% of 209 lung cancer patients
experienced cancer shrinkage, according to data assessed by an
independent review committee - company
    ** Adds that based on the positive results, it is closing
the study and will request a meeting with the U.S. FDA before
submitting a marketing application for the drug
    ** SRNE says it could potentially also file for approval of
the drug with regulatory agencies of other countries
    ** Including session's gain, stock down ~60% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))